A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs CGF 166 (Primary)
- Indications Hearing loss
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 14 Nov 2019 Planned End Date changed from 9 Oct 2019 to 5 Dec 2019.
- 14 Nov 2019 Planned primary completion date changed from 9 Oct 2019 to 4 Dec 2019.
- 14 Nov 2019 Status changed from recruiting to active, no longer recruiting.